Divestment package may not appease ACCC concerns over pathology merger
A proposed divestment remedy by Australian Clinical Labs does not fully address concerns that its takeover of a rival would harm competition, the country’s antitrust watchdog has said.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.